The 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2024) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity.
Topics
- The effect of lipotoxicity and the pathophysiology of CVD
- The relationship between diabetes, obesity, and congestive heart failure
- The roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes
- The role of obesity in the development of cardiometabolic conditions
- The role of incretins in the management of diabetes, obesity, and related complications
- Comprehensive management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia
- The role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D
- The evidence supporting the use of SGLT2 inhibitors and GLP1ra`s to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD
- Fatty liver disease and its relationship to diabetes and CVD
- The role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- The impact on clinical practice of recent CVD, CHF & CKD outcome trials
- The pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD
- Best practices for the prevention and management of CHF
- The impact on clinical practice of lipid CV outcome trials, including IMPROVE -IT, FOURIER, REDUCE -IT, ODYSSEY-Outcomes
- The role of Coagulation and new anti-coagulation agents in prevention of CVD and CVA
- The Cardiorenal Syndrome
- Reducing morbidity and mortality through being able to match the correct medications to the appropriate patients
Who should Attend
- Endocrinologists
- Cardiologists
- Oncologists
- Gastroenterologists
- Diabetologists
- Internists
- Pediatricians
- OBGYNs
- Nurse practitioners
- Dietitians
- Pharmacists
- Other health care professionals
